Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 168 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
1671 4.9 months Malignant Mesothelioma 5 Chemotherapy
Ohio State University Comprehensive Cancer Center United States 5/2004
Treatment Details: Patients: This Phase II study involved 27 patients with malignant mesothelioma. Treatment: The treatment consisted of the administration of the chemotherapy drug, capecitabine (xeloda),
 
1672 4.9 months Metastatic or recurrent breast cancer 5 Chemotherapy
The Ottawa Hospital Cancer Centre Canada 9/2010
Treatment Details: Patients: This study involved women with metastatic or recurrent breast cancer who had previously received chemotherapy. Patients were divided into 2 treatment groups. Group 1 consisted o
 
1673 4.9 months Malignant pleural mesothelioma 4 Chemotherapy
Memorial Sloan Kettering Cancer Center United States 3/2014
Treatment Details: Patients: This study involved malignant pleural mesothelioma patients who were divided into two separate treatment groups. Group A consisted of 33 patients with a median age of 65 years; 7
 
1674 4.8 months Metastatic colorectal cancer 4 Biologic therapy
Memorial Sloan-Kettering Cancer Center United States 7/2010
Treatment Details: Patients: This phase II study involved 47 previously treated metastatic colorectal cancer patients. The median age was 62 years and 59% were male. Treatment: Patients were treated with
 
1675 4.8 months Malignant Mesothelioma 5 Chemotherapy
Scripps Clinic United States 11/2001
Treatment Details: Patients: This Phase II study involved 10 patients with malignant mesothelioma. Treatment: The treatment consisted of the chemotherapy drug doxorubicin (adriamycin) (high-dose) with the
 
1676 4.8 months Metastatic NSCLC 4 Chemotherapy
University of Kansas Medical Center United States 8/2002
Treatment Details: Patients: This Phase II trial involved 18 patients with metastatic non-small cell lung carcinoma. Treatment: The treatment consisted of a drug called pyrazoloacridine. Toxicity: One
 
1677 4.7 months Malignant Mesothelioma 5 Chemotherapy
University of Chicago Medical Center United States 2/2001
Treatment Details: Patients: This Phase II study involved 17 patients with malignant mesothelioma. Treatment: The treatment consisted of the chemotherapy drug, gemcitabine. Toxicity: Two patients di
 
1678 4.6 months Advanced hepatocellular (liver) carcinoma 4 Chemotherapy
Chang Gung Memorial Hospital Taiwan Region 11/2002
Treatment Details: Patients: This Phase I-II study involved 50 patients with advanced hepatocellular (liver) carcinoma who had not received chemotherapy before. Thirty-five patients entered the Phase II porti
 
1679 4.4 months GBM (recurrent) 5 Biologic therapy
Mayo Clinic United States 8/2005
Treatment Details: Patients: This Phase II trial involved 65 patients with newly diagnosed glioblastoma multiforme (GBM). There were 38 men and 27 women, and the median age was 54 years. Prior to the start o
 
1680 4.4 months metastatic breast cancer 4 Radiation
Cleveland Clinic Brain Tumor Institute United States 1/2006
Treatment Details: Patients: This Phase III study involved 515 patients of whom 397 had brain metastases from advanced non-small-cell lung cancer or breast cancer. The patients were divided into two groups, w
 
Page 168 of 187  | Previous Page  | Next Page